ViaCyte and W.L. Gore & Assoc. said today that they inked a co-development deal for the synthetic pancreas ViaCyte is developing to treat diabetes.
The San Diego-based company’s Encaptra device is designed to be seeded with stem cells engineered to become pancreatic cells and implanted under the skin. The newly created pancreatic cells generate insulin and other hormones about 3 months after implantation, which then pass through a semi-permeable membrane that blocks white blood cells to prevent an immune response against the implanted cells.
Get the full story at our sister site, Drug Delivery Business News.
The post ViaCyte, Gore ink co-development deal for synthetic pancreas appeared first on MassDevice.
from MassDevice http://ift.tt/2o7sThR
Cap comentari:
Publica un comentari a l'entrada